AMARIN CORP PLC\UK Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AMARIN CORP PLC\UK stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $59.00K, a 3.51% increase year-over-year.
- AMARIN CORP PLC\UK stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $57.00K, a 53.28% decline year-over-year.
- AMARIN CORP PLC\UK stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $122.00K, a 49.17% decline year-over-year.
- AMARIN CORP PLC\UK stock issued during period, value, employee stock purchase plan for the quarter ending 2023-09-30 was $2.00K.
- AMARIN CORP PLC\UK stock issued during period, value, employee stock purchase plan for fiscal 2025 was $140.00K, a 15.70% increase from fiscal 2024.
- AMARIN CORP PLC\UK stock issued during period, value, employee stock purchase plan for fiscal 2024 was $121.00K, a 63.33% decline from fiscal 2023.
- AMARIN CORP PLC\UK stock issued during period, value, employee stock purchase plan for fiscal 2023 was $330.00K, a 45.45% decline from fiscal 2022.
- AMARIN CORP PLC\UK stock issued during period, value, employee stock purchase plan for fiscal 2022 was $605.00K, a 63.33% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $59.00K 10-Q · filed 2026-07-29 | |
| 2025-12-31 | $140.00K 10-K · filed 2026-03-02 | |
| 2025-06-30 | $57.00K 10-Q · filed 2026-07-29 | |
| 2024-12-31 | $121.00K 10-K · filed 2026-03-02 | |
| 2024-06-30 | $122.00K 10-Q · filed 2025-10-29 | |
| 2023-12-31 | $330.00K 10-K · filed 2026-03-02 | |
| 2023-09-30 | $2.00K 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $240.00K 10-Q · filed 2024-10-30 | |
| 2022-12-31 | $605.00K 10-K · filed 2024-02-29 | |
| 2022-06-30 | $383.00K 10-Q · filed 2023-11-01 | |
| 2021-12-31 | $1.65M 10-K · filed 2023-03-01 | |
| 2021-06-30 | $1.03M 10-Q · filed 2022-10-27 | |
| 2020-12-31 | $1.96M 10-K · filed 2023-03-01 | |
| 2020-06-30 | $848.00K 10-Q · filed 2021-11-03 | |
| 2019-12-31 | $2.17M 10-K · filed 2022-03-01 | |
| 2019-06-30 | $837.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.04M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | |
| 2018-06-30 | $423.00K 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |